Format

Send to

Choose Destination
Semin Neurol. 2019 Apr;39(2):188-199. doi: 10.1055/s-0039-1678580. Epub 2019 Mar 29.

Neuroimaging in Dementias.

Author information

1
Department of Radiology of Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut.

Abstract

Dementia is a global health issue, the burden of which will worsen with an increasingly aging population. Alzheimer's disease (AD) is the most common dementia, with 50 to 60% of all dementias attributable to AD alone, while the rest are mostly due to frontotemporal lobar dementia, dementia with Lewy bodies, Parkinson's disease dementia, and vascular dementia. Diagnosis of dementias is made clinically with the aid of other testing modalities including neuroimaging. While the role of imaging has traditionally been to exclude reversible causes of dementia, positron emission tomography (PET) with 18-fluorine fluorodeoxyglucose and magnetic resonance imaging now are increasingly used more for definitive diagnosis of dementia in the prodromal stages and to aid with formulating the differential diagnoses. Introduction of molecular imaging modalities such as amyloid PET and tau PET have improved diagnostic certainty in the clinical trial setting and promise to find their way into the clinic in the near future. In this review, we will focus on the multimodality imaging of dementias especially AD and its differential diagnoses.

PMID:
30925612
DOI:
10.1055/s-0039-1678580
[Indexed for MEDLINE]

Conflict of interest statement

M.-K.C. reports research support from Eli Lilly and clinical trials from Merck, outside the submitted work. Additionally, he received research support from the Dana Foundation and a pilot grant from Yale Alzheimer's Disease Research Center (NIH P50AG047270). S.M. reports no conflict of interest.

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center